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chart-review study of PsA patients was conducted among physicians in hospitals/
private practices to collect de-identified data on patients recently treated with a 
biologic as part of usual care. Physicians from UK/Germany/France/Italy/Spain (5EU) 
were screened for practice-duration and patient-volume and recruited from a large 
panel to be geographically representative in each country. Eligible patient charts (> 2) 
were randomly selected from a sample of prospective patients visiting each center/
practice during the screening period. Physicians abstracted patient diagnosis, treat-
ment patterns/dynamics and patient symptomatology/disease status. Results: 
Between Jan2011-Dec2012, 454 PsA patients (mean age:48.8yrs;female:49.6%) on 
2nd-line biologic after 1st-line anti-TNF failure were identified. Mean time-to-1st-
line anti-TNF from diagnosis was 51.6months; mean time on 1st-line anti-TNF was 
18.3months (patients < 6/7-12/13-24/> 24months:33%/21%/19%/27%). Top-3 1st line 
anti-TNFs observed were: etanercept(38%), adalimumab(32%), and infliximab(27%). 
The top-5 reasons for 1st-line anti-TNF discontinuation were ‘long-term efficacy 
failure’, ‘disease worsened’, ‘side-effects not tolerated’, ‘insufficient-improve-
ment’, and ‘initial failure of efficacy’. Mean time on current 2nd-line biologic was 
18.5months (patients < 6/7-12/13-24/> 24months:28%/21%/25%/27%). Current 2nd-
line biologics (top-5) included: adalimumab(39%)/etanercept(31%)/infliximab(14%)/
golimumab(11%)/abatacept(2%). Top-5 reasons for choice of 2nd-line biologic were 
‘mechanism of action’, ‘prevention of structural damage’, ‘improve signs/symp-
toms’, ‘disease worsened’, ‘positive personal experience’. Key lab measures docu-
mented were: ESR-21.7mm/h and CRP-8.3mg/dl. Among patients with available 
data, current HAQ was 1.1, Swollen Joint Count was 1.9 and Tender Joint Count 
was 3.4. Current disease severity per physician judgment (mild:moderate:severe) 
were: 48%:47%:5%. Current disease severity (mild:moderate:severe) by time on 1stline 
anti-TNF biologic (< 6/7-12/13-24/> 24months) were 47%:48%:5% / 55%:42%:3% / 
49%:48%:4% / 44%:49%:7% respectively. ConClusions: Among PsA pts on their 2nd 
biologic who experienced anti-TNF failure, 54% discontinued their 1st line anti-TNF 
regimen within 12months of initiation and continue to have considerable disease 
burden despite current 2nd line biologic.
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objeCtives: Until 2010 the cost of biological treatments in Rheumatoid Arthritis 
(RA) was increased annually by 15% in our hospital. In 1stJanuary 2011, a Hospital 
Commission and Protocol of Biological Therapies were created to improve the 
cost-effectiveness usage of biological drugs in RA. To evaluate the economic impact 
associated with a biological therapy prioritization Protocol for RA patients in the 
Hospital of Sagunto. Methods: Observational, ambispective study comparing 
the associated cost of biotreated RA patients pre-protocol (2009-2010) versus 
post-protocol periods (2011-2012). Inclusion criteria: RA patients treated with 
Abatacept (ABA) Adalimumab (ADA), Etanercept (ETN) or Infliximab (IFX) for at 
least 6 months during the study period (2009-2012). ETN was selected as 1st line 
therapy because our successful experience of ETN 25 mg/weekly in certain RA 
patients, its subcutaneous administration and lowest theoretical cost per patient 
in Spain. Cost savings and economic impact were calculated using Spanish offi-
cial prices. Results: In the pre-protocol period (2009-2010), total expenses were 
increased by 110,000€ , up to 1,761,000€ in 2010 (11,362€ pat/year). After protocol 
implementation, total expenses decreased by 53,676€ on the 2010-2011 period, and 
149,200€ on the 2011-2012 period. On the 2010-2011 period the cost of biological 
therapy per patient-year decreased 355€ (11,007€ pat/year) and additional 653€ (up 
to 10,354€ pat/year) by 2012, with a cumulative effect of the protocol implementa-
tion of 1,008€ per patient-year. In the pre-protocol period, the annual cost/patient 
was 10.812€ with ETN, 10.942€ with IFX, 12.961€ with ADA and 12.739€ with ABA. 
By 1st Jan 2013, the annual cost per patient was 9,469€ with ETN, 10,579€ with 
IFX, 11,117€ with ADA and 13,540€ with ABA. ConClusions: The creation of our 
Commission of Biological Therapies is key to rational management of RA patients 
and optimization of resources, allowing us to save 200,000€ after 2-year efficiency 
protocol implementation.
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objeCtives: To describe the current medical management of Rheumatoid 
Arthritis (RA) patients in routine practice in a national representative sample of 
patients, focusing on biological agents (BA) uptake. Methods: The EGB database 
is a 1/97 representative sample of the national claims database covering the whole 
French population. RA patients were identified as adults (age > 18) benefiting from 
full coverage (“ALD” eligibility criteria) for RA (ICD-10 codes M05-06) on January 1, 
2009. Patients treated by BA were defined as RA patients with at least one claim 
for at least one BA over the period. BA-naïve treated patients were identified by 
the absence of a BA claim during the first 3 months of the study period, followed 
by at least one BA claim. Results: Over the 3-year period, 236 patients had a BA 
reimbursed and 5,336 deliveries by pharmacists were observed. The proportion 
of BA users, either alone or in combination, was 14.0% in 2009, and 70 patients 
(32.7%) used a BA in combination with methotrexate. Among patients treated by 
BA, 85.2% used at least one TNF inhibitor during the study period. Etanercept had 
the highest delivery record (58.1%), followed by adalimumab (28.8%) and infliximab 
(15.3%). Among the whole group of patients treated by BA, 13.6% were delivered 
rituximab at least once. Over the period, a proportion of 73.3% of patients had one 
BA agent only, 19.1% experienced one switch and 7.6% had two or more switches. 
differed between those in remission vs. those who were not: Tender Joint Count: 
2.3-vs-6.1, Swollen Joint Count: 1.2-vs-4.2, 100mm VAS score: 18.6-vs-42.8, HAQ: 
0.7-vs-1.6 and DAS28: 2.6-vs-4.4. ConClusions: More than half of the patients 
were not in remission in this diverse cohort of RA patients in 5-EU and they experi-
enced disproportionate level of disease burden. As the line of treatment increased, 
proportion of individuals achieving remission decreased. These observed patterns 
warrant further scrutiny to determine the best practices and improve remission 
rates, thereby alleviating patient burden.
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objeCtives: To assess the clinical characteristics of patients with RA receiving their 
first biologic in EU and the US. Methods: A multi-country medical chart-review 
study of RA patients was conducted among physicians (majority: rheumatologists) 
in hospitals and private practices to collect de-identified data on patients who were 
recently treated with a biologic as part of usual care. Physicians from UK, Germany, 
France, Italy and Spain (5EU) and the US were screened for duration of practice and 
patient volume and recruited from a large panel to be geographically representa-
tive in each country. Eligible RA patient charts (> 5) were randomly selected from 
a sample of prospective patients visiting each center/practice during the screen-
ing period. Physicians abstracted patient diagnosis, treatment patterns/dynamics 
and patient symptomatology/disease status. Results: In 4Q2012, 434 physicians 
(5EU:337; US:97) abstracted 2085 (5EU:1534; US:551) eligible RA patient charts; cur-
rent biologic patterns (5EU/US) were: 1st line (78%/69%), 2nd line (16%/21%) & 3rd+ 
line (6%/11%). 1577 (5EU:1199; US: 378) patients were on their first biologic. Mean 
age – 5EU:50.8yrs, US:52.8yrs; female – 5EU:73%; US:73%. Mean time-to-1st biologic 
(5EU/US) from diagnosis was 40/28 months; mean time on current 1st biologic (5EU/
US) was 24/34 months. Top-3 biologic treatments observed were – etanercept (5EU/
US:37%/42%), adalimumab (5EU/US:34%/32%), and infliximab (5EU/US:8%/10%). 
The top-5 reasons for biologic treatment initiation were the same across 5EU/US 
(‘mechanism of action’, ‘improve signs/symptoms’, ‘prevent structural damage’, 
‘positive personal experience’, ‘inhibits disease progression’). Key lab measures 
documented were (5EU/US): ESR (22.7/24.2mm/h) and CRP (10.9/2.5mg/dl). Current 
disease severity per physician judgment (mild:moderate:severe) were: 5EU-
57%:37%:6%, US-67%:29%:3%. Among patients with available data, current HAQ 
(5EU:1.2/US:0.7), DAS28 (5EU:3.4/US:2.5), 100mmVAS (5EU:3.5/US:2.3), Swollen Joint 
Count (SWC) (5EU:2.6/US:2.0) and Tender Joint Count (TJC) (5EU:3.9/US:2.8) differed 
within between 5EU and US. ConClusions: Among RA patients receiving their 
first biologic, disease severity differed between 5EU and US, with patients in 5EU 
with relatively higher burden.
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objeCtives: To evaluate physician assessment of patient eligibility and even-
tual use of biologics in RA, AS, and PsA in the US. Methods: A multi-country 
cross-sectional survey of physicians (primarily rheumatologists) was conducted 
in the US. Physicians were screened for biologic patient volume (> 2RA biologic 
patients/week, > 5AS biologic patients/month, > 5PsA biologic patients/month) 
and recruited from a large physician-panel to be geographically representative. 
Practice characteristics, patient-volume, physician perceptions and practice pat-
terns were assessed; physicians’ target patient population was grouped into 2 
categories, based on physician input: Group1 – patients perceived to be eligible 
for biologics, Group2 – patients who ended up receiving biologics within Group1. 
Summary statistics across the US are reported. Results: In 4Q2012, 97 physicians 
participated in the study. Mean age: 47.6yrs; female: 30%. Main practice: private 
office (non-hospital):46%. Patient volume per physician was: total-1904, RA-419, 
AS-82, PsA-145. Average frequency of patient encounters were (RA/AS/PsA; weeks): 
11/12/11. Physician judgment of patient disease severity were (average across their 
patients): RA – mild:28%/moderate:47%/severe:25%, AS – mild:31%/moderate:43%/
severe:26% and PsA – mild:30%/moderate:44%/severe:27%. Physician assess-
ment of patient eligibility and use of biologics were: within RA-mild-patients – 
Group1:21%/Group2:14%, within RA-moderate-patients – Group1:63%/Group2:51%, 
within RA-severe-patients – Group1:81%/Group2:70%; within AS-mild-patients – 
Group1:32%/Group2:24%, within AS-moderate-patients – Group1:66%/Group2:55%, 
within AS-severe-patients – Group1:79%/Group2:69%; within PsA-mild-patients – 
Group1:30%/Group2:23%, within PsA-moderate-patients – Group1:66%/Group2:55%, 
within PsA-severe-patients – Group1:81%/Group2:71%. Among the top-3 biologic 
treatments used, etanercept, adalimumab, and infliximab were observed throughout 
RA, AS and PsA. ConClusions: Across the markets, between 30-45% of biologic 
eligible patients (per physician perception) within moderate/severe disease sever-
ity groups did not end up receiving a biologic therapy across RA/AS/PsA cohorts. 
Reasons behind these patterns and the impact on subsequent patient outcomes 
warrant further scrutiny.
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diSEaSE BurdEn aMong PatiEntS with PSoriatic arthritiS who havE 
ExPEriEncEd firSt linE tuMor nEcroSiS factor inhiBitor rEgiMEn 
failurE in thE EuroPEan union
Narayanan S.1, Lu Y.2, Hutchings R.2, Baskett A.2
1Ipsos Healthcare, Gaithersburg, MD, USA, 2Ipsos Healthcare, London, UK
objeCtives: To assess treatment patterns and disease burden among PsA patients 
on 2nd-line biologics after 1st-line anti-TNF failure. Methods: A multi-country 
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was inadequate response from traditional disease-modifying anti-rheumatic drugs 
(DMARDs) alone (54.9%), followed by symptom control (13.4%). Among the remaining 
responses, clinical data (e.g., results from clinical trials) was cited most frequently in 
the UK (17.1%) compared to Germany/Spain (9.0%/4.7%), while personal experience 
was cited most in Germany (15.3%) vs. UK/Spain (2.7%/0.9%). Inadequate response 
to DMARDs was most frequently reported for adalimumab (61.5%) vs. etanercept 
(46.9%) or other biologics (40.2%); inadequate DMARD symptom control was more 
cited for etanercept (18.8%) vs. adalimumab (11.1%) or other biologics (9.8%). Among 
the 23 patients who switched to a second biologic agent, 72.7% were switched due 
to inadequate response to the first biologic agent. ConClusions: Across the 
three study countries, prescribers most frequently initiated biologic therapy due 
to inadequate response or lack of symptom control on traditional DMARDs. Other 
reasons varied by country, however differences across biologic agents prescribed 
were minimal.
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objeCtives: Cervical Dystonia (CD), the most common adult-onset dystonia, is 
characterised by involuntary contractions of the cervical muscles that result in 
abnormal, sustained, and painful postures of the head, neck and shoulders. Annual 
prevalence rate of CD in Europe is approximately 117 per million. To date, very 
few studies assessed the burden of the disease, and those published focused on 
costs of specific treatments. The objective of this study was to describe health care 
resource utilisation of patients with CD during the first year after diagnosis in 
the UK. Methods: In this retrospective cohort study, adult patients with a first 
ever diagnosis of primary or secondary CD (Read code: F138200 Spasmodic torti-
collis) between January 2007 and December 2011 were selected from The Health 
Improvement Network (THIN), a large UK Primary Care database. Patients were 
required to have a follow-up time of at least 24 months after diagnosis. Analyses 
performed described demographic and clinical characteristics at diagnosis and 
all-cause utilization of CD-related health care resources including treatment dur-
ing follow up. Results: This study included 4,497 patients, 65.40% were female, 
median age at diagnosis was 41 years old and 8.05% were diagnosed with depression. 
During that first year, patients had on average 6 visits to the GP (SD: 5.45) and were 
newly referred most frequently to the orthopaedist (5.09%); less than 2% of patients 
had an all-cause hospitalisation and less than 1% underwent neurosurgery; 80.23% 
were managed with pharmacological treatment for CD, and the most commonly 
prescribed drugs were analgesics (69.85%) and benzodiazepines (41.23%); 14.65% 
received physical therapy. ConClusions: This study provides first-time estimates 
of the health care resource utilisation related to management of patients with CD 
in UK during the first year. To describe the complete burden of CD further research 
will have to investigate secondary care data and longer time horizon.
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objeCtives: To analyze the potential cost savings associated with utilization of 
a quota for biosimilar RA medicines in a biologic naïve but potentially biologic 
eligible population (those defined as severe). Methods: High patient numbers 
in rheumatoid arthritis (RA) and biologic therapy costs place significant pressures 
on health care budgets. Currently biologic therapies are underutilized in severe RA 
(DAS Score ≥ 3.7) patient populations that may be eligible for treatment. Biosimilar 
treatments are expected to reach the market (for the top 3 molecules adalimumab, 
etanercept and infliximab) by 2017 and may provide an avenue to reduce treatment 
costs and increase patient access to these agents. Biologic naïve RA populations 
were estimated for France, Germany and the UK as severe RA patients are assumed 
to be eligible for biologic therapy. Total cost of applying biologic treatment to a 
50% quota of the estimated eligible patient population was compared to a situa-
tion of initiating patients on a biosimilar equivalent with a price point 30% lower 
than the originator. Reinvestment potential was calculated, defining how many 
more patients could be treated with yearly savings. Results: By 2017, when all 3 
biosimilars are expected to be available, the assumed 50% quota resulted in yearly 
savings of € 98 million for the UK, € 351 million for Germany and € 26 million for 
France compared to the budget impact of using the originator. If these savings were 
reinvested potentially 40%, 36% and 39% of the remaining biologic naïve patients 
could be initiated on biosimilar treatment in the UK, Germany and France respec-
tively. ConClusions: The cost savings from biosimilar adoption in naive severe 
RA patients presented potentially increase access by removing budgetary pressures 
from health care systems. Proactive payer encouragement for biosimilar utilization 
is necessary through the use of guidelines and prescription quotas so that health 
care systems can realize significant savings.
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At 18 months, drug survival rate of the mix of first-line biologics was 71.8% [95% 
CI: 60.1% - 80.6%]. ConClusions: Claims database is a useful tool to describe the 
medical management of RA patients. These observations suggest that BA clinical 
use in RA disease management in France is similar to other existing European 
registries data.
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objeCtives: Etanercept 50mg/week (ETN50) has demonstrated efficacy in rheu-
matoid arthritis (RA), psoriatic arthropathy (PA) and ankylosing spondylitis (AS) 
patients. In certain patients in sustained clinical remission, a dose reduction to 
etanercept 25 mg/week (ETN25) could be done. Determine the economic impact 
of ETN25 in RA, PA and AS patients in sustained clinical remission. Methods: 
Observational, retrospective cohort of patients treated with ETN50 that achieve 
and maintain clinical remission (DAS28< 2.6 or BASDAI< 2) during 1 year and slow 
worsening of structural changes, enrolled in an off-label program (January 2006-June 
2013) to switch ETN50 to ETN25. Economical impact was assessed using Enbrel® 
Spanish official prices. Results: From January 2006 to June 1, 2013, 98 RA, 40 PA, 
47 AS patients were treated with ETN50; 39 (24%) patients (18 women; age 53±7 
years; 24 RA, 7 PA, 8 AS) received ETN25 for at least 0.5 years (2.6±2.0 years; range 
0.5-7.3 years). At June 1, 2013, 29 (74%) patients continued on ETN25. RA patients: 17 
continued on ETN25, 5 patients discontinued due to reactivation of RA (4 switched to 
ETN50 and 1 switched to adalimumab, all regained clinical remission) and 2 patients 
due to adverse reactions. PA patients: 4 continued on ETN25, 2 patients discontinued 
due to reactivation of PA (switched to ETN50 regaining clinical remission) and 1 
patient due to adverse reaction. All AS patients continued on ETN25. Total associ-
ated savings with ETN 25 throughout the 7-year observation period were 622.073€ , 
leading to treat 52 additional patients with ETN50 for a year without increasing ETN 
total costs. ConClusions: ETN25 produces cost savings when used in patients 
in clinical remission for at least 1 year with ETN50. At a time when therapy cost is 
an unavoidable component of health care treatment decisions, ETN25 could be a 
cost-effective option for selected RA, PA and AS patients.
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objeCtives: Switching or dose escalation of TNF inhibitors is an option for rheu-
matoid arthritis (RA) patients unresponsive or with a partial response to first-line 
treatment. Drug costs increase with higher dosing but the frequency and impact 
of dose escalation on other costs is not well known. A literature review of biologic 
dose escalation in RA was conducted to assess how often it occurs and the economic 
impact to payers. Methods: A search of PubMed, EMBASE, Cochrane, and Centre of 
Disseminated Reviews was conducted for TNF inhibitors in inflammatory arthritis 
diseases. Searches were focused on dose escalation and economic terms in RA. 
Limits were Human, English and time frame (2003 to 2013). A weighted proportion 
of dose escalators in RA was calculated for each drug as an alternative to reporting 
ranges. Results: Forty-one publications were identified with 36 reporting values 
for dose escalation in RA. The proportion of dose escalators varied widely: adali-
mumab 7.5 to 36%, etanercept 0 to 22%, and infliximab 0 to 80%. Various definitions 
of dose escalation led to the wide range. The weighted proportion of dose escalators 
for each drug was adalimumab 14.9%, etanercept 4.9%, and infliximab 41.7%. Six 
studies reported economic data comparing dose escalators to non-dose escalators. 
Adalimumab drug costs increased 27 to 43% with total costs increasing 28 to 34%; 
infliximab drugs costs increased 6 to 75%, RA-related costs increased 25 to 54%, 
and total costs increased 15% to 35%. Lowest costs were reported with etanercept: 
drug costs increased 3.2 to 19%, RA-related costs increased 4.5%, and total costs 
increased 2.2 to 15%. ConClusions: Pooled results demonstrated dose escalation 
in RA occurred most frequently with infliximab and least frequently with etaner-
cept. Not only were biologic costs increased, but also RA-related and total costs. 
Etanercept was associated with the lowest cost increases.
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objeCtives: This study aimed to describe the rationale for selection of initial bio-
logic therapy and changes in biologic therapy among patients with RA in Germany, 
Spain, and the United Kingdom (UK). Methods: This retrospective, observational 
medical chart review captured patient data via 118 Spanish, German, and British 
rheumatologists. Patients( ≥ 18 years) had a confirmed diagnosis of RA between 
January 2008 and December 2010, and received a biologic therapy for ≥ 3 months and 
had ≥ 12 months of follow-up. Physicians recorded all RA regimens and rationale for 
drug selection. Results: The 656 patients (n= 328; Germany: n= 111, Spain: n= 106, 
UK: n= 111) were 71.3% female, had a mean (standard deviation) age of 48.3 (12.6) 
years at diagnosis and mean 28-joint Disease Activity Score of 5.1±1.2 at biologic 
initiation. Patients most frequently initiated biologic therapy with adalimumab 
(41%) or etanercept (38%). The most common reason for initial biologic treatment 
